JP2008513027A - フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 - Google Patents

フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 Download PDF

Info

Publication number
JP2008513027A
JP2008513027A JP2007532656A JP2007532656A JP2008513027A JP 2008513027 A JP2008513027 A JP 2008513027A JP 2007532656 A JP2007532656 A JP 2007532656A JP 2007532656 A JP2007532656 A JP 2007532656A JP 2008513027 A JP2008513027 A JP 2008513027A
Authority
JP
Japan
Prior art keywords
pal
protein
peg
activity
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513027A5 (https=
Inventor
アレハンドラ ゲイムズ，
リン ワン，
ウーミ キム，
メアリー ストラウブ，
マリアン ジー． パッチ，
エミール カッキス，
ダン オッペンハイマー，
ポール エー． フィッツパトリック，
ロバート ヘフト，
レイモンド シー． スティーブンス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of JP2008513027A publication Critical patent/JP2008513027A/ja
Publication of JP2008513027A5 publication Critical patent/JP2008513027A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2007532656A 2004-09-17 2005-09-19 フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 Pending JP2008513027A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61077004P 2004-09-17 2004-09-17
US65195005P 2005-02-09 2005-02-09
PCT/US2005/033895 WO2006034373A2 (en) 2004-09-17 2005-09-19 Variants and chemically-modified variants of phenylalanine ammonia-lyase

Publications (2)

Publication Number Publication Date
JP2008513027A true JP2008513027A (ja) 2008-05-01
JP2008513027A5 JP2008513027A5 (https=) 2008-11-06

Family

ID=36090659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532656A Pending JP2008513027A (ja) 2004-09-17 2005-09-19 フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体

Country Status (6)

Country Link
US (1) US7553653B2 (https=)
EP (1) EP1814984A2 (https=)
JP (1) JP2008513027A (https=)
AU (1) AU2005286763A1 (https=)
CA (1) CA2580679A1 (https=)
WO (1) WO2006034373A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516428A (ja) * 2013-04-18 2016-06-09 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
ES2582459T3 (es) 2010-02-04 2016-09-13 Biomarin Pharmaceutical Inc. Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014018822A2 (en) * 2012-07-26 2014-01-30 Casa Luker S.A. Methods for increasing the production of phenolic compounds from theobroma cacao
WO2015161019A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
SG11202105668PA (en) 2018-12-14 2021-06-29 Codexis Inc Engineered tyrosine ammonia lyase
CA3154817A1 (en) * 2019-10-17 2021-04-22 James Nolan Pegylated kynureninase enzymes and uses thereof for the treatment of cancer
WO2021158686A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
CN115298308A (zh) * 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
EP4204554A4 (en) 2020-08-28 2024-08-21 Codexis, Inc. MODIFIED PROTEASE VARIANTS
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
CN118475692A (zh) 2021-11-01 2024-08-09 森蒂斯生物公司 工程化亮氨酸脱羧酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
US20250108095A1 (en) * 2023-09-28 2025-04-03 Aperiam Bio, Inc. Degradation of toxins in vivo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102712A1 (en) * 2000-07-24 2002-08-01 Pcbu Services, Inc. Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DK75593D0 (https=) * 1993-06-25 1993-06-25 Novo Nordisk As
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
EP1476563B1 (en) * 2002-02-26 2008-09-17 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
US20080124275A1 (en) * 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102712A1 (en) * 2000-07-24 2002-08-01 Pcbu Services, Inc. Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516428A (ja) * 2013-04-18 2016-06-09 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP2020185016A (ja) * 2013-04-18 2020-11-19 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP7129715B2 (ja) 2013-04-18 2022-09-02 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド

Also Published As

Publication number Publication date
US20070048855A1 (en) 2007-03-01
WO2006034373A3 (en) 2006-11-02
WO2006034373A8 (en) 2006-08-10
WO2006034373A2 (en) 2006-03-30
WO2006034373A9 (en) 2006-05-11
CA2580679A1 (en) 2006-03-30
EP1814984A2 (en) 2007-08-08
US7553653B2 (en) 2009-06-30
AU2005286763A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
JP2008513027A (ja) フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
JP5670183B2 (ja) 原核生物フェニルアラニンアンモニアリアーゼの組成物、及び、その組成物の使用方法
US20240035013A1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US7531341B1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
BR112019016634A2 (pt) polipeptídeos, sequência de polinucleotídeos modificados por engenharia, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo de fenilalanina amônia liase modificado por engenharia em uma célula hospedeira e para tratar e/ou prevenir os sintomas de fenilcetonúria em um indivíduo, composição, e, uso
US20230212239A1 (en) Inhibitors of cbl autoinhibition and related methods
JP2023512683A (ja) 操作されたロイシンデカルボキシラーゼ
US20240228983A1 (en) Modified Red Blood Cells and Uses Thereof For Treating Hyperuricemia and Gout
US7285408B2 (en) Crystalline form of an n231 mutant catalytic domain of ADAM33 and methods of use thereof
HK1135141B (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025